There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.
Researchers from the RIKEN Brain Science Institute in Japan have shown in mouse models that idiopathic autism could be caused by epigenetic abnormalities in hematopoietic cells during fetal development which resulted in immune dysregulation in the brain and gut.
Fat cells surrounding the lymph nodes could switch jobs in response to a distant infection, taking on immune cell functions, researchers at Johns Hopkins University reported in the May 3, 2022, online issue of CellMetabolism.
In a study reported in the April 27, 2022, online edition of Nature, an international team of researchers has for the first time demonstrated a three-way interaction between neurons, immune cells and plaques as a key component of atherosclerosis.
Researchers have uncovered a new pathway via which cancer cells evade the effects of radiation by deploying self-inflicted – but reversible – DNA breaks to stop the cell cycle and ensure their survival. The lesions are caused by caspase-activated DNase (CAD), an enzyme involved in DNA fragmentation during cell death. In response to radiation, tumor cells activate CAD, causing genome-wide DNA breaks at sites involved in DNA repair.
Researchers at the University of Pennsylvania have gained new insight into how different inflammatory conditions reinforce each other via trained innate immunity.
Researchers have uncovered a new pathway via which cancer cells evade the effects of radiation by deploying self-inflicted – but reversible – DNA breaks to stop the cell cycle and ensure their survival.
Screening a panel of potential autoantigens, investigators at the Karolinska Institute have identified four autoantigens that are targeted by the T cells of multiple sclerosis patients.
Antibiotics drugs discovery, Ursula Theuretzbacher told the audience at the 2022 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), has more than one challenge to overcome.
Researchers from the Center for Genome Engineering within South Korea's Institute for Basic Science have developed a new gene-editing platform that could be the final missing piece of the puzzle in gene-editing technology, by making editing of mitochondrial DNA possible.